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Superinfections with Streptococcus 
pneumoniae and Staphylococcus aureus 
have been a well-known complication of 
seasonal influenza. More recently, inva-
sive pulmonary aspergillosis (IPA) was 
described as another important compli-
cation. Influenza-associated IPA (IAPA) 
has so far been predominantly described 
in critically ill patients admitted to the 
intensive care unit (ICU) with influenza 
pneumonia [1–3]. Following a number 
of single-center case series, the Dutch-
Belgian Mycoses Study Group (DB-MSG) 
evaluated the incidence of IAPA in the 
largest cohort study of patients admitted 
to the ICU with influenza so far. In this 
study, 19% of the 432 patients admitted to 
the ICU during 7 consecutive influenza 
seasons were diagnosed with IAPA. The 
study also demonstrated that, in patients 
admitted to the ICU with community-
acquired pneumonia, the detection of 
influenza was strongly associated with a 
subsequent diagnosis of IPA and half of 
the patients diagnosed with IAPA died in 
the ICU [1].
In this issue of Clinical Infectious 
Diseases, a single-center retrospective co-
hort study performed over 5 consecutive 
influenza seasons at a large tertiary care 
center in Alberta, Canada, reports on the 
incidence of IPA in 111 patients admitted 
to the ICU for respiratory failure caused 
by an influenza infection [4]. These data 
are a welcome addition to the data cur-
rently available in the literature. In con-
trast with the incidence of IAPA of 12% 
to 28% described in Europe and Asia so 
far, Schwartz et  al found a substantially 
lower incidence of 7.2% (8 of 111 pa-
tients). Before we start wondering about 
why the incidence of IAPA in Canada 
may be lower than in Europe or Asia, it is 
important to put this incidence of 7% into 
perspective. Indeed, apart from patients 
undergoing remission induction chemo-
therapy for acute myeloid leukemia, 
patients with severe graft-versus-host 
disease, and perhaps also lung transplant 
patients, no other patient population has 
an incidence of IPA as high as 7%.
Histopathological evidence of the pres-
ence of Aspergillus species from a sterile 
body site remains the gold standard of an 
invasive aspergillosis diagnosis. However, 
sampling lung tissue in an ICU patient is 
clearly not without risk and actually rarely 
performed. Sputum or tracheal aspirate 
cultures are a low-cost and easy-to-perform 
diagnostic test, but the sensitivity when 
used to diagnose IPA in ICU patients does 
not exceed 50% [5]. Several non–culture-
based assays are now available to demon-
strate the presence of Aspergillus in blood or 
airway samples and testing for the presence 
of galactomannan (GM), a cell-wall com-
ponent of Aspergillus, is the most validated 
of these non–culture-based tests. Because 
most studies that evaluated the value of 
GM testing for the diagnosis of invasive 
aspergillosis in ICU patients included few 
patients with a proven infection, doubts re-
main regarding its value in ICU patients. 
However, in a unique prospective study 
that was conducted in the setting of a very 
high autopsy rate, a substantial number of 
proven infections were included. In this 
unique study, testing for the presence of 
GM on bronchoalveolar lavage (BAL) fluid 
had a sensitivity of 88% and specificity of 
87%. One of the most striking observa-
tions in this study was that GM testing on 
BAL identified 11 of a total of 26 (autopsy) 
proven IPA cases. Without GM testing 
these cases would have been missed if only 
fungal cultures would have been used. As 
expected, GM testing on serum performed 
substantially poorer [6, 7]. In the study by 
Schwartz and colleagues, clinicians tested 
for the presence of GM on BAL in as few 
as 16 of the 111 patients. It is therefore very 
likely that the incidence of 7% would have 
been higher if GM had been tested on BAL 
in all patients.
However, a true difference in the inci-
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the case and several hypotheses can be pos-
tulated here. Differences in the incidence of 
invasive aspergillosis have been linked to 
single nucleotide polymorphisms (SNPs) 
in several genes of the innate immune 
system. Single nucleotide polymorphisms 
in the Pentraxin 3 (PTX3) gene decrease 
antifungal clearance and phagocytosis 
by neutrophils and therefore increase the 
susceptibility to invasive mold infections. 
These PTX3 SNPs have been linked to an 
increased fungal infection risk in each of 
the 3 patient groups at highest risk for inva-
sive mold infections: solid organ and allo-
geneic stem cell transplant recipients and 
patients with acute leukemia [8–10]. Future 
studies should look at the role of PTX3 and 
other genetic risk factors in IAPA.
Apart from genetic factors, environ-
mental factors are likely to play a role as well, 
as IAPA is often diagnosed in the first days 
after and even on the day of ICU admission. 
This suggests that the infection is caused 
by Aspergillus spores inhaled by the patient 
preceding hospital admission. Therefore, 
it is likely that differences in Aspergillus 
spore counts in the air (eg, rural rather than 
urban, dry versus wet climate) will influence 
the risk of IAPA. Apart from diagnostic and 
genetic factors, the way healthcare is organ-
ized locally may also influence the incidence 
of IAPA across countries and continents. 
Indeed, so far, data on IAPA come almost 
entirely from tertiary-care ICU centers. But 
even within these tertiary-care ICU popula-
tions, the specific patient referral policy in a 
country is likely to influence the IAPA risk. 
For instance, if extracorporal membrane 
oxygenation is only performed at the sites 
included in a specific study, the patients ad-
mitted at these ICUs will often be referred 
from first-care hospitals after conventional 
ventilatory support has been shown to be 
insufficient. These differences in ventilatory 
failure may not be reflected in conventional 
APACHE scores. Also, patients admitted to 
the ICU in tertiary-care centers may more 
often have specific underlying disease in 
which tertiary-care hospitals are typically 
specialized (eg, vasculitis, solid organ trans-
plantation, autoimmune diseases). Finally, 
we have more speculative explanations 
for the observed differences in IAPA. 
Differences in influenza vaccination pol-
icies will influence the uptake of influenza 
vaccination and could change the severity 
of illness of an influenza infection in the 
population under study. Even more specu-
lative is that the reported higher incidence 
of IAPA in recent years might be caused by 
the widespread use of neuraminidase in-
hibitors in patients infected with influenza. 
Fundamental research indicates that neur-
aminidase plays a role in the host immunity 
against Aspergillus species and blocking 
neuraminidase could increase the risk for 
Aspergillus superinfection [11]. Finally, the 
reported incidences of IAPA in ICU patients 
may only reflect the tip of iceberg. Some pa-
tients in the study by Schwartz et al survived 
without treatment while others died despite 
the best antifungal therapy. It might be that 
Aspergillus superinfection is quite common 
during influenza but only clinically relevant 
in patients admitted to the ICU.
But what is the clinical relevance of 
IAPA? Is it just an innocent bystander 
or is it truly one of the steps on the path 
from influenza infection to the death of 
these patients in the ICU? Half of the pa-
tients with IAPA in the cohort study from 
Schwartz et al died. This is in line with the 
reported mortality of IAPA cases in the 
DB-MSG study. To try to answer the ques-
tion of whether the significantly higher 
mortality observed in patients with IAPA 
can be attributed to the Aspergillus super-
infection or if it is just a marker of overall 
disease severity, we performed a mortality 
analysis on the DB-MSG study cohort. 
Remember, in this study 432 patients ad-
mitted to the ICU with influenza were 
included, of whom 117 were immuno-
compromised according to the European 
Organization for Research and Treatment 
of Cancer/Invasive Fungal Infections 
Cooperative Group and the National 
Institute of Allergy and Infectious Diseases 
Mycoses Study Group (EORTC/MSG) cri-
teria [12]. A total of 83 of the 432 patients 
(19%) were diagnosed with IAPA, and the 
90-day mortality was 51%, which was sub-
stantially higher than the mortality in the 
349 patients without IAPA (28%; P < .001). 
A  Kaplan–Meier survival curve was 
made for patients with and without IAPA 
(Figure  1A) and a Cox regression ana-
lysis was performed to determine whether 
IAPA, as a time-dependent covariate, 
was independently associated with 
90-day mortality, using the independent 
covariates as depicted in Figure 1B [13]. In 
the immunocompromised subgroup, 38 
patients or 32% developed IAPA and 71% 
of them died. The Cox regression ana-
lysis showed that the emergence of IAPA 
was independently associated with 90-day 
mortality (adjusted hazard ratio [aHR], 
1.944; 95% confidence interval [CI], 
1.307–2.891; P = .001) (Figure 1B) as were 
age (aHR, 1.032; 95% CI, 1.018–1·046), 
APACHE II score (aHR, 1.046; 95% CI, 
1.023–1.069), diabetes (aHR, 1.599; 95% 
CI, 1.092–2.342), being immunocom-
promised according to EORTC/MSG 
criteria (excluding corticosteroid use) 
(aHR, 1.670; 95% CI, 1.146–2.434), and 
corticosteroid therapy before ICU admis-
sion (aHR, 1.118; 95% CI, 1.035–1.207 per 
0.1 mg/kg per day prednisone equivalent). 
These results strongly suggest that IAPA is 
independently associated with mortality 
in patients admitted to the ICU with influ-
enza. Although we acknowledge that ob-
servational data can never prove a causal 
relationship with 100% certainty, the as-
sociation of IAPA and mortality was inde-
pendent of confounders such as severity of 
illness and being immunocompromised at 
ICU admission. This finding, again, con-
firms the relevance of diagnosing IAPA in 
the ICU. In accordance with recent litera-
ture, corticosteroid exposition preceding 
the ICU admission in patients with severe 
influenza significantly impacted mortality 
as well, and strongly suggests that caution 
is needed regarding the use of adjuvant 
corticosteroid therapy for patients with 
severe pneumonia during the influenza 
season [14, 15].
Many outstanding questions remain to 
be resolved. To answer these questions, 
the quality of future research on IAPA 
needs to be improved further. For this we 
will need a consensus definition of IAPA 
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a group of experts in the field of inva-
sive fungal infections and intensive care 
medicine met to discuss and eventually 
formulate a workable set of definitions. 
We expect these to become publicly avail-
able in early 2020. Future studies should 
try to find risk factors for IAPA other 
than those already found. This will allow 
for stratification of patients included 
in studies on the prevention of IAPA 
(eg, with systemic or inhaled antifungal 
prophylaxis). It will also help the clinician 
when a decision needs to be made upon 
the invasiveness of diagnostic procedures 
to be done. Indeed, in a patient at very 
high risk for IAPA, a more invasive diag-
nostic strategy is justified. Once the diag-
nosis is made, the optimal therapy for 
IAPA needs to be found. Until new data 
arise, it is logical to treat these patients 
according to guidelines on the treatment 
of invasive aspergillosis. However, pa-
tients with Aspergillus tracheobronchitis 
may need to be treated differently. Also, 
it may well be that at least a subset of pa-
tients with IAPA can be treated for just a 
few weeks rather than a typical duration 
of at least 6 weeks and often many months 
for patients with a probable invasive as-
pergillosis according to the EORTC/
MSG definition. Finally, we think that a 
better understanding of the underlying 
immunological mechanism and patho-
genesis of IAPA is clearly needed because 
this may eventually lead to targeted pre-
vention or therapy.
In conclusion, IAPA is a frequent and 
potentially lethal complication of influ-
enza in critically ill patients. While its in-
cidence may vary between geographical 
regions and centers, small primary-care 
ICUs will also see these patients if a 
high awareness among physicians is in 
place. Data like in the study by Schwartz 
et al demonstrate that, in patients with 
influenza admitted to the ICU with re-
spiratory insufficiency, a diagnostic 
bronchoscopy should be done to look 
for tracheobronchitis and to biopsy 
visible lesions but also to sample BAL 
fluid. If the patient is not yet intubated, 
a very experienced bronchoscopist is 
often still able to perform a “mini-BAL” 
in just a few minutes while the patient 
is receiving high-flow nasal oxygen 
therapy. Galactomannan testing should 
be done on serum and preferentially 
also on BAL fluid. At ICU admission, 
a fungal culture on sputum or tracheal 
aspirates should be done. If IAPA is ex-
cluded on admission but progressive 
radiological and/or clinical deterior-
ation is observed during or after ICU 
admission, a repeated radiological and/
or bronchoscopic evaluation is needed 
to rule out IAPA (again).
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